PubRank

A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir

Clinical Trial ID NCT01918631

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01918631

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chronic hepatitis B: update 2009. Hepatology 2009 16.08
2 EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012 14.55
3 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004 13.18
4 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 10.58
5 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 6.67
6 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 5.65
7 Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008 2.90
8 Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2010 2.81
9 Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2010 2.37
10 Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006 2.28
11 Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007 2.11
12 Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2012 1.86
13 Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006 1.56
14 Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010 1.47
15 Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007 1.24
16 Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011 1.02
17 Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat 2011 0.98
18 Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther 2012 0.85
Next 100